# Expanded Access Protocol Thymus Transplantation

> **NCT02274662** · PHASE4 · COMPLETED · sponsor: **Sumitomo Pharma Switzerland GmbH** · enrollment: 11 (actual)

## Conditions studied

- Poor Thymic Function
- Immunodeficiency
- Athymia
- Immunoreconstitution
- Thymus Transplantation
- Low T Cell Numbers

## Interventions

- **BIOLOGICAL:** Cultured Thymus Tissue
- **PROCEDURE:** Blood Draw
- **DRUG:** Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus

## Key facts

- **NCT ID:** NCT02274662
- **Lead sponsor:** Sumitomo Pharma Switzerland GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2023-08
- **Final completion:** 2023-08
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02274662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02274662, "Expanded Access Protocol Thymus Transplantation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02274662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*